{"filing":{"accession_number":"0001213900-26-092838","cik":"0001611746","ticker":"SPRC","company_name":"SciSparc Ltd.","form":"6-K","filing_date":"2026-08-24","report_date":"2026-08-24","primary_document":"ea0303150-6k_scisparc.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1611746/000121390026092838/ea0303150-6k_scisparc.htm"},"events":[{"id":29099,"run_id":26626,"accession_number":"0001213900-26-092838","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"The press release announces a significant intellectual property milestone: publication of a U.S. patent application covering a novel MDMA-N-acylethanolamines combination for treating PTSD, anxiety, and eating disorders through SciSparc's subsidiary NeuroThera's ongoing collaboration with Clearmind Medicine. This represents advancement of the joint IP portfolio (now thirteen published patent applications globally) and occurs amid FDA finalization of guidance on psychedelic drug development explicitly including MDMA. While this is a material operational and strategic development for the company's drug development pipeline, it does not fit neatly into the specific event categories (it is neither a discrete M\u0026A transaction, a regulatory approval, nor a material contract announcement in the traditional sense), making operational_other the most appropriate classification.","company_name":"SciSparc Ltd.","ticker":"SPRC","filing_date":"2026-08-24","form":"6-K","submitted_at":null,"items":[{"id":31263,"accession_number":"0001213900-26-092838","item_number":"EX-99.1","item_title":"ea030315002ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The press release announces a significant intellectual property milestone: publication of a U.S. patent application covering a novel MDMA-N-acylethanolamines combination for treating PTSD, anxiety, and eating disorders through SciSparc's subsidiary NeuroThera's ongoing collaboration with Clearmind Medicine. This represents advancement of the joint IP portfolio (now thirteen published patent applications globally) and occurs amid FDA finalization of guidance on psychedelic drug development explicitly including MDMA. While this is a material operational and strategic development for the company's drug development pipeline, it does not fit neatly into the specific event categories (it is neither a discrete M\u0026A transaction, a regulatory approval, nor a material contract announcement in the traditional sense), making operational_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-24T13:22:46.869590+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":31263,"accession_number":"0001213900-26-092838","item_number":"EX-99.1","item_title":"ea030315002ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The press release announces a significant intellectual property milestone: publication of a U.S. patent application covering a novel MDMA-N-acylethanolamines combination for treating PTSD, anxiety, and eating disorders through SciSparc's subsidiary NeuroThera's ongoing collaboration with Clearmind Medicine. This represents advancement of the joint IP portfolio (now thirteen published patent applications globally) and occurs amid FDA finalization of guidance on psychedelic drug development explicitly including MDMA. While this is a material operational and strategic development for the company's drug development pipeline, it does not fit neatly into the specific event categories (it is neither a discrete M\u0026A transaction, a regulatory approval, nor a material contract announcement in the traditional sense), making operational_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-24T13:22:46.869590+00:00","company_name":"SciSparc Ltd.","ticker":"SPRC","filing_date":"2026-08-24"}]}